| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 23.10. | ZEO ScientifiX, Inc.: ZEO ScientifiX Positioned for New Growth as Florida Opens Stem Cell Market | 281 | ACCESS Newswire | New Florida stem cell law provides ZEO with new pathways to market and sell regenerative therapy products and advance clinical research initiatives FORT LAUDERDALE, FL / ACCESS Newswire / October 23... ► Artikel lesen | |
| 23.10. | Zeo ScientifiX, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 15.09. | Zeo ScientifiX, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 29.07. | Zeo ScientifiX, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 21.07. | Zeo ScientifiX, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 09.07. | Zeo ScientifiX, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 09.07. | Zeo ScientifiX, Inc.: ZEO ScientifiX Positions for National Growth as Stem Cell Market Opens in Florida | 482 | ACCESS Newswire | ZEO Launches New Website and Agency Partnerships to Address Expected Biologics Market Demand Following Florida's New Stem Cell Law FORT LAUDERDALE, FL / ACCESS Newswire / July 9, 2025 / ZEO ScientifiX... ► Artikel lesen | |
| ZEO SCIENTIFIX Aktie jetzt für 0€ handeln | |||||
| 24.06. | Zeo ScientifiX, Inc.: ZEO ScientifiX Launches Physician-Focused Masterclass Ahead of Florida's SB-1768 Law Implementation | 247 | ACCESS Newswire | FORT LAUDERDALE, FL / ACCESS Newswire / June 24, 2025 / ?ZEO ScientifiX, Inc.?("ZEO" or the "Company") (OTCQB:ZEOX), a clinical-stage biopharmaceutical company pioneering the research and development... ► Artikel lesen | |
| 24.06. | Zeo ScientifiX, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 16.06. | Zeo ScientifiX, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 18.02. | Zeo ScientifiX, Inc.: ZEO ScientifiX Strengthens Leadership Team With The Appointment of Dr. Peter Everts as Chief Scientific and Technology Officer | 394 | ACCESS Newswire | FORT LAUDERDALE, FL / ACCESS Newswire / February 18, 2025 / ZEO ScientifiX, Inc. ("ZEO" or the "Company") (OTCQB:ZEOX), a clinical-stage biopharmaceutical company focused on the research and development... ► Artikel lesen | |
| 11.02. | ZEO ScientifiX, Inc.: ZEO ScientifiX Provides Business Update to Stockholders and the Investment Community | 334 | ACCESS Newswire | FORT LAUDERDALE, FL / ACCESS Newswire / February 11, 2025 / ZEO ScientifiX, Inc. ("ZEO" or the "Company") (OTCQB:ZEOX), a clinical-stage biopharmaceutical company focused on the research and development... ► Artikel lesen |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| AVIDITY BIOSCIENCES | 71,55 | +0,53 % | Novartis CEO paid top dollar for Avidity to become a 'leader in neuromuscular diseases' | ||
| ARCUTIS BIOTHERAPEUTICS | 30,730 | -0,10 % | Why Shares in Arcutis Biotherapeutics Surged Again This Week | ||
| OLEMA PHARMACEUTICALS | 26,070 | +4,05 % | Biotech-Party! Olema-Aktie explodiert über 136 Prozent - die Hintergründe | Prämie dank Übernahme? Spektakuläre Studienergebnisse? Es ist keine Seltenheit, dass Biotech-Titel aus dem Stand an einem Tag prozentual dreistellig an Wert gewinnen können. Bei Olema Pharmaceuticals... ► Artikel lesen | |
| ARCELLX | 73,00 | -2,61 % | Arcellx: Stifel bekräftigt "Buy"-Rating im Vorfeld der ASH-Konferenz 2025 | ||
| PRAXIS PRECISION MEDICINES | 184,25 | -3,72 % | Praxis Precision Medicines, Inc.: Praxis to present latest preclinical and clinical advancements across leading epilepsy portfolio at the 2025 American Epilepsy Society (AES) Annual Meeting | ||
| JANUX THERAPEUTICS | 34,740 | +10,23 % | Janux Therapeutics: Günstige Gelegenheit | Janux Therapeutics hat mit seiner innovativen Plattformtechnologie im letzten Jahr das Interesse vieler Investoren geweckt - nicht zuletzt aufgrund von Übernahmegerüchten. Doch unabhängig von einem... ► Artikel lesen | |
| IMMUNOVANT | 23,950 | +2,70 % | Immunovant, Inc. - 8-K, Current Report | ||
| COGENT BIOSCIENCES | 39,720 | +3,06 % | Will Cogent Biosciences' (COGT) Breakthrough Therapy Transform GIST Treatment? Analysts Think So | ||
| QIAGEN | 41,790 | +1,79 % | JEFFERIES stuft QIAGEN NV auf 'Buy' | NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat die Einstufung für Qiagen mit einem Kursziel von 57 US-Dollar auf "Buy" belassen. Die Profitabilität dürfte 2026 zumindest stabil bleiben... ► Artikel lesen | |
| DYNE THERAPEUTICS | 20,800 | -4,01 % | Dyne Therapeutics: Bernstein hebt Kursziel wegen günstigem Risiko-Ertrags-Verhältnis an | ||
| DISC MEDICINE | 92,53 | -1,68 % | Jefferies bestätigt Kaufempfehlung für Disc Medicine angesichts wichtiger Katalysatoren | ||
| SUMMIT THERAPEUTICS | 17,640 | +8,96 % | Summit Therapeutics: Fortschritte bei Krebsstudien und solide Finanzlage auf Jefferies-Konferenz in London | ||
| APOGEE THERAPEUTICS | 70,92 | +4,59 % | Apogee Therapeutics Provides Pipeline Progress and Reports Third Quarter 2025 Financial Results | Pipeline programs continue to advance, with four clinical data readouts anticipated in 2026; APG777 trial readout timelines accelerated, with Phase 1b in asthma and APEX 52-week Part A data in AD... ► Artikel lesen | |
| VERA THERAPEUTICS | 29,430 | +0,65 % | Vera Therapeutics Submits Biologics License Application to U.S. FDA through Accelerated Approval Program for Atacicept for the Treatment of Adults with IgA Nephropathy | Atacicept received FDA Breakthrough Therapy Designation for the treatment of IgANORIGIN Phase 3 trial met its primary endpoint at the prespecified interim analysis of proteinuria reduction with 46%... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 4,370 | +0,58 % | Could Recursion Pharmaceuticals Be the Next Big Artificial Intelligence (AI) Stock? |